2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Radionuclide-Drug Conjugates (RDCs)
  5. RDC Peptide Isoform

RDC Peptide

The targeting ligands of RDC mainly include antibodies, peptides, and small molecules, etc. Peptides are of growing interest for use in radiopharmaceuticals largely due to their size, which has ramifications on stability, biological circulation, and synthesis. Peptide-radionuclide conjugate drugs can achieve ideal drug delivery, which combines the excellent tissue penetration and low immunogenicity of peptides to improve treatment efficiency and reduce side effects related to systemic toxicity. In recent years, a variety of peptide-radionuclide conjugate drugs have been approved by the FDA and are playing an increasingly important role in cancer diagnosis and treatment.

RDC Peptide Related Products (20):

Cat. No. Product Name Effect Purity
  • HY-106244A
    DOTATATE acetate
    		99.82%
    DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT). DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
  • HY-106244
    DOTATATE
    		99.87%
    DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT). DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
  • HY-P3440
    WL12
    		99.99%
    WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression.
  • HY-P5126
    DOTA-LM3
    		98.22%
    DOTA-LM3 is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 and 68 Ga-DOTA-LM3. 68 Ga-DOTA-LM3 shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis. DOTA-LM3 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
  • HY-P5128
    DOTA-JR11
    		98.81%
    DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research. DOTA-JR11 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
  • HY-W046355
    Fmoc-D-Dap(Boc)-OH
    		99.56%
    Fmoc-D-Dap(Boc)-OH is an amino acid derivative with an Fmoc protecting group, which can be used to synthesize bioactive peptide mimetics, such as DOTA-modified peptides and their metal chelates with cancer diagnostic effects.
  • HY-P10273A
    DOTA-Octreotide TFA
    DOTA-Octreotide TFA is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide TFA is used for research of cancer through combination with radioactive elements. DOTA-Octreotide TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
  • HY-P5126A
    DOTA-LM3 TFA
    		99.30%
    DOTA-LM3 TFA is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis. DOTA-LM3 (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
  • HY-P10131
    3BP-3940
    		99.96%
    3BP-3940 is a highly potent fibroblast activation protein (FAP)-targeting peptide for theranostics. 3BP-3940 is often coupled with radionuclides for tumor diagnosis and treatment. 3BP-3940 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
  • HY-D2363
    DOTA.SA.FAPi TFA
    		99.26%
    DOTA.SA.FAPi TFA inhibits fibroblast activation protein (FAP) with an IC50 of 0.9 nM. DOTA.SA.FAPi TFA targets protease PREP with an IC50 of 5.4 μM. DOTA.SA.FAPi TFA can be used a PET tracer, when labeled with 68Ga, and used for research about cancer. DOTA.SA.FAPi (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
  • HY-P2218
    Anditixafortide
    Anditixafortide (Pentixather) is an endoradiotherapeutic vector. Anditixafortide is a CXCR4-targeting peptide derivative. Anditixafortide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
  • HY-158266
    DOTA-PSMA-EB-01
    DOTA-PSMA-EB-01 (Compound LNC1003) is a specific inhibitor of PSMA (IC50= 10.77 nM).DOTA-PSMA-EB-01 enhances the uptake and retention time of 177Lu in tumors. DOTA-PSMA-EB-01 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
  • HY-P5520
    GB-6
    GB-6 is a short linear peptide that targets the gastrin releasing peptide receptor (GRPR). GRPR is overexpressed in pancreatic cancer. Based on the tumor selectivity and tumor-specific accumulation properties of GB-6, GB-6 labeled with near infrared (NIR) fluorescent dyes or radionuclide netium-99m (99mTc) can be used as a high-contrast imaging probe. GB-6 has excellent in vivo stability, with tumor to pancreatic and intestinal fluorescence signal ratios of 5.2 and 6.3, respectively, in SW199 0 subcutaneous xenograft models. GB-6 can rapidly target tumors and accurately delineate tumor boundaries, which has broad application prospects.
  • HY-P5297
    DOTA-CXCR4-L
    DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
  • HY-P10292
    NOTA-Pep-1L
    NOTA-Pep-1L specifically targets the IL13RA2 receptor for tumor imaging. NOTA-Pep-1L can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
  • HY-P2112
    DOTA-NOC
    DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5. DOTA-NOC can be used for labeling with various radiometals, and development of radiopeptide imaging. DOTA-NOC can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
  • HY-P10273
    DOTA-Octreotide
    DOTA-Octreotide is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide is used for research of cancer, through combination with radioactive elements. DOTA-Octreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
  • HY-P10444
    DOTA Conjugated JM#21 derivative 7
    DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney. DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
  • HY-P10307
    DOTA-ubiquicidin (29–41)
    DOTA-ubiquicidin (29-41), an antimicrobial peptide fragment derivative, can be used for synthesis of [68Ga]Ga-DOTA-Ubiquicidin29-41 and then used for imaging of infectious processes using PET/CT. DOTA-ubiquicidin (29–41) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
  • HY-P10220
    NOTA-COG1410
    NOTA-COG1410 forms triggering receptor expressed on myeloid cells 2 (TREM2) targeting radioligand for discovery and diagnosis of digestive system tumors through positron emission tomography/computed tomography. NOTA-COG1410 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).